Phase II Evaluation Of CP4071 In Previously Treated Advanced Sarcomas
- Determine the efficacy, in terms of response rate, of CP4071 in patients with
previously treated, locally advanced or metastatic soft tissue sarcoma.
- Determine the clinical toxic effects of this drug in these patients.
OUTLINE: Patients receive oral CP4071 daily. Treatment continues in the absence of disease
progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Primary Purpose: Treatment
Robert N. Taub, MD, PhD
Herbert Irving Comprehensive Cancer Center
United States: Federal Government
|Herbert Irving Comprehensive Cancer Center||New York, New York 10032|